28 November 2016 - Pfizer’s Ibrance breast cancer pill may have been a huge hit in the US, where it has achieved sales above a billion dollars a year already – but the company is gearing up for a rough ride with the UK’s NICE.

NICE is already reviewing cost-effectiveness of Ibrance (palbociclib) in breast cancer after European approval earlier this month.

But David Montgomery, medical director – oncology for Pfizer UK and Ireland, told Pharmaphorum that although the drug has been successful in US hospitals, its use as an add-on therapy could pose problems due to the way NICE does its calculations.

Read Pharmaphorum article